anonymous
Guest
anonymous
Guest
We also thought we had promotable advantages and a better price with Dulera over Adair and Symbicort. How many DPP4S have entered the market after Januvia and how are they doing? Point is, "Me-Toos" are DOA in today's health care market. Launching a SGLT2 at this point is too little too late.